Medpage Today on MSN20d
Overcoming the Challenges of Applying CAR T-Cell Therapy to Solid Tumors
An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...
Hosted on MSN1y
FDA probing serious risk of T-cell malignancies in CAR-T cell therapy patients (update)
The regulator said it had determined that the risk of T-cell malignancies applied to all currently approved BCMA-directed and CD19-directed genetically modified autologous CAR-T cell immunotherapies.
Nature12mon
Enabling T cell therapy for established solid tumors using genetic-enhancing modifiers
More importantly, most patients treated with CD19 or B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells will eventually relapse despite having initial complete responses.
The Victoria Advocate14d
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
The Company's lead program for autoimmune disease is P-BCMACD19-ALLO1, a dual CAR-T targeting BCMA and CD19. New preclinical data demonstrate P-BCMACD19-ALLO1's potential in both autoimmune ...
Longview News-Journal22d
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody Recent clinical data from CD19 and BCMA targeted ...
News Medical10mon
CAR-specific monoclonal FMC63 antibodies for CD19 CAR expression evaluation
In CAR-T therapy, CD19 is now the most extensively used target. It has been confirmed to be effective and safe for the treatment of CLL, B-ALL and B cell lymphoma. FMC63, an IgG2a mouse monoclonal ...
Taiwan News2d
CAR T Cell Therapy Market Demand Trends, Industry Analysis, and Forecast Insights (2024-2032)
The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean. Request To ...
Mena FN22d
Aditum Bio And Leads Biolabs Announce The Formation Of Oblenio Bio To Develop A Tri-Specific T-Cell Engager For Autoimmune Disorders
Recent clinical data from CD19 and BCMA targeted therapies have demonstrated compelling efficacy in difficult-to-treat autoimmune diseases. Despite these promising results, there is a continued ...
Stockhouse14d
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
The Company's lead program for autoimmune disease is P-BCMACD19-ALLO1, a dual CAR-T targeting BCMA and CD19. New preclinical data demonstrate P-BCMACD19-ALLO1's potential in both autoimmune disease ...
manilatimes22d
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody Recent clinical data from CD19 and BCMA targeted therapies ...
Medindia21d
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Leads Biolabs grants Oblenio Bio an exclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody OAKLAND, Calif. and NANJING, China, Nov. 7, 2024 ...